Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lineage Cell Therapeutics reports successful Q4, eyes strategic partnerships

Lineage Cell Therapeutics is advancing with promising programs like OpRegen, focusing on financial discipline and milestone achievements to drive shareholder value in 2023.
Despite net losses in 2022, Lineage's strong cash position, successful clinical outcomes, and strategic partnerships position the company for growth and leadership in cell therapy.

Lineage Cell Therapeutics reports progress in Q1 despite financial challenges

Lineage Cell Therapeutics showcased progress in OpRegen's clinical findings and financial performance in Q1 2023.
The company faces challenges in financials and market education but holds strengths in strategic partnerships and therapeutic advantages.
Opportunities lie in market positioning, collaborations, and continued innovation to drive growth and market adoption for Lineage's therapies.

Lineage Cell Therapeutics reports stable finances and advances key programs

Lineage Cell Therapeutics shows financial stability with strong cash reserves and a strategic focus on advancing key pipeline programs.
Despite challenges in patient enrollment and cell delivery, the company remains innovative and adaptable in exploring gene therapy solutions.
Positive FDA feedback on the OPC1 program and ongoing exploration of partnerships and advancements position Lineage for future growth and success.

Lineage Cell Therapeutics reports strong Q3 performance and eyes growth

Lineage Cell Therapeutics demonstrated financial stability, innovation in cell therapy, and progress in regenerative medicine programs during Q3 2023.
Challenges include study completion, safety concerns, enrollment trends, and strategic resource allocation for future growth.
Opportunities lie in market expansion, collaborations in neurology, therapeutic advancements, and regulatory success for the company.
Overall, Lineage Cell Therapeutics is positioned for growth through strategic partnerships and advancements in regenerative medicine.

Lineage Cell Therapeutics reports stable finances and program advancements

Lineage Cell Therapeutics showcased financial stability, program advancements, and strategic decisions in the Q4 2023 earnings call, emphasizing progress in OpRegen and OPC1 programs.
While facing challenges in managing expenses and uncertainties in program timelines, the company highlighted opportunities in partnerships, patient inclusion, and innovation for future growth.
Analyst questions focused on clinical outcomes, financing decisions, and program updates, reflecting investor interest in OpRegen program advancements and market potential.

Lineage Cell Therapeutics reports Q1 results, highlights partner support

Lineage Cell Therapeutics' Q1 2024 performance reflects revenue challenges but highlights strong partner support and operational preparedness.
The company faces financial losses amid investments in R&D but showcases a commitment to strategic growth and long-term success.
Challenges in revenue generation and data validation are balanced by opportunities in clinical trial efficiency, market demand, and therapeutic expansion.
Overall, Lineage's focus on innovation, partnerships, and operational readiness positions it for potential growth and success in the cell therapy space.

Lineage Cell Therapeutics extends cash runway, advances key programs

Lineage Cell Therapeutics reported financials for Q3 2024, extending cash runway and showcasing progress in key programs.
Strengths include advancements in OpRegen and ReSonance programs, with a strategic focus on manufacturing and partnerships.
Challenges lie in financial performance, maintaining cash discipline, and meeting study endpoints, while opportunities arise from collaborations and program advancements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) is saddened to report the passing of its long-serving Chairman of the Board of Directors, Mr. Alfred D. Kingsley, and offers its deepest condolences to Mr. Kingsley's family for their loss. Mr. Kingsley served as Chairman of the Company's Board of Directors since July 2009, and was a significant contributor in the evolution of the Company into a clinical-stage biotechnology company developing allog.

Lineage Announces Changes to Board of Directors

NOVI, Mich.--(BUSINESS WIRE)-- #oneLineage--Lineage announces the appointment of Shellye Archambeau to the Board of Directors of Lineage's operating subsidiary, Lineage Logistics Holdings, LLC.

Lineage Announces Appointment of New Board Member

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has.

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation, a non-profit organization dedicated to advancing innovative research and improving quality of life for individuals impacted by paralysis, are proud to again collaborate to present the 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS"). Th.

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), will be presented at the 2024 Retinal Cell &.

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that preclinical results as part of a surgical development study evaluating the survival and distribution of RG6501 (OpRegen) will be presented at the 2024 Association for Research in Vision and Ophthalmology Annual Meeting (2024 ARVO). The meeting will be held May 5-9, 2024, in Sea.

RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting

Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Ioana Hone - Head of IR Brian Culley - CEO Jill Howe - CFO Conference Call Participants Joe Pantginis - H.C Wainwright Jack Allen - Baird Kristen Kluska - Cantor Fitzgerald Mayank Mamtani - B. Riley Sean McCutcheon - Raymond James Michael Okunewitch - Maxim Group Operator Welcome to the Lineage Cell Therapeutics Fourth Quarter and Fiscal Year-End 2023 Conference Call.

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2023 Earnings Call Transcript

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter and full year 2023 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update. “Throughout 2023, our team has continued to advance our clinical and preclinical pipeline of d.

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2023 financial and operating results on Thursday, March 7, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, March 7, 2024, at 4:30 p.m. Eastern T.

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today the clearance, by the U.S. Food and Drug Administration (FDA), of its Investigational New Drug amendment (INDa) for OPC1, an investigational allogeneic oligodendrocyte progenitor cell transplant for the treatment of spinal cord injury (SCI). Pursuant to the INDa, Lineage has initiat.

Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of its previously announced registered direct offering for the purchase and sale of 13,461,540 of the company's common shares at an offering price of $1.04 per common share. The price per share was the closing price of the company's common shares on NYSE American on Febr.

Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into a definitive agreement with certain investors for the purchase and sale of 13,461,540 of the company's common shares in a registered direct offering at an offering price of $1.04 per common share. The price per share was the closing price of the company's common.

Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results showing retinal structure improvements with RG6501(OpRegen) from a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) in geographic atrophy (GA) secondary to advanced age-related macular degeneration (AMD), will be presented at the 2024 Angiogenesis,.

RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that the Company has submitted an Investigational New Drug amendment (INDa) to the U.S. Food and Drug Administration (FDA), for OPC1, its investigational allogeneic oligodendrocyte progenitor cell transplant, for the treatment of spinal cord injury (SCI). Receipt of FDA clearance of.

Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury

Gevo

Quantum Computing

By corporate protocol and just plain old common sense, when it comes to penny stocks to buy, your first instinct should be this: don't. Yeah, I know that's not exactly a sexy opener for the topic at hand.

3 Penny Stocks to Buy for the Next Bull Run

Start Time: 16:30 January 1, 0000 5:12 PM ET Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q3 2023 Earnings Conference Call November 09, 2023, 16:30 PM ET Company Participants Brian Culley - CEO Jill Howe - CFO Gary Hogge - SVP, Clinical and Medical Affairs Ioana Hone - Head, IR Conference Call Participants Joseph Pantginis - H.C. Wainwright Abigail Gray - Baird Kristen Kluska - Cantor Fitzgerald Operator Welcome to the Lineage Cell Therapeutics Third Quarter 2023 Conference Call.

Lineage Cell Therapeutics, Inc. (LCTX) Q3 2023 Earnings Call Transcript

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the third quarter ended September 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update. “The Lineage team has continued to advance our clinical and preclinical pipeline of d.

Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2023 financial and operating results on Thursday, November 9, 2023, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, November 9, 2023, at 4:30 p.m. Eastern Time/1:30.

Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive Officer, has been invited to present as part of the “Mapping the Future of Geographic Atrophy” session at Eyecelerator 2023, on Thursday, November 2nd, 2023, at 10am PT. The session will also feature executive presenters from Apellis P.

RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting

Athersys

Unity Biotechnology Inc

Longevity stocks have started to come on many investors' radars. These companies come with the promise of stable returns over the long run as human life continues to stretch further ahead.

Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,746,324, entitled “Large Scale Production of Retinal Pigment Epithelial Cells”. The patent, which has been exclusively licensed to Lineage, has an expected expiration date of July 28, 2036. RG65.

Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells

Lineage (LCTX) rises 10% on positive imaging analyses results from the phase I/IIa study of OpRegen in patients with geographic atrophy secondary to age-related macular degeneration.

Lineage (LCTX) Up 10% on Upbeat Data From Eye Disease Study

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the results of imaging analyses demonstrating rapid improvement in outer retinal structure from patients enrolled in a Phase 1/2a clinical study of RG6501 (OpRegen) (ClinicalTrials.gov Identifier: NCT02286089), which were reviewed by multiple, independent reviewers, were presen.

RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Lineage Cell Therapeutics is a clinical-stage biotechnology company focused on developing cell therapies for degenerative diseases. The shares trade for just over a buck apiece. Five analyst firms have reissued Buy/Outperform ratings on the stock, with price targets ranging from $4.00 to $7.00 a share. The company is partnered with Genentech around its main developmental program and that is targeting a large potential market.

A Second Look At Lineage Cell Therapeutics

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Brian M. Culley, Lineage's Chief Executive Officer, will present at the Cantor Fitzgerald 2023 Global Healthcare Conference, in a fireside chat hosted by Kristen Kluska, Managing Director, Biotechnology Equity Research, Cantor Fitzgerald & Co., on September 27th, 2023 at 9:.

News for Lineage Cell Therapeutics Inc Stock (LCTX)